Streetbeat News

Analyst Ratings

UTZ

Analysts have provided 11 recent ratings for Utz Brands (NYSE:UTZ), with an average price target of $16.18, down from $18.78. The ratings include 1 bullish, 7 somewhat bullish, and 3 indifferent. Notable analysts from firms like Piper Sandler, RBC Capital, and Goldman Sachs have adjusted their price targets and ratings, reflecting a mix of raised and lowered expectations. Utz Brands has shown a revenue growth rate of 2.49% as of September 30, 2023, a net margin of 4.3%, but a lower ROE of 2.29% and ROA of 0.57%, with a high debt-to-equity ratio of 1.42.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:01 pm

SYF

Synchrony Financial (NYSE:SYF) has been rated by 10 analysts in the last quarter with 2 bullish, 4 somewhat bullish, 2 indifferent, and 2 somewhat bearish ratings. The average 12-month price target is $35.2, down 4.56% from the previous $36.88. Analysts from firms like Goldman Sachs, JMP Securities, Piper Sandler, Morgan Stanley, JP Morgan, HSBC, and Citigroup have adjusted their price targets and ratings, reflecting their views on the company's market position and financial performance. Synchrony Financial has shown strong financial indicators such as a 19.21% revenue growth rate, a net margin of 17.78%, and a ROE of 4.81%.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

VSEC

Analysts have recently provided ratings for VSE Corporation (NASDAQ:VSEC), with 6 analysts offering a 12-month average price target of $75.33, a high estimate of $85.00, and a low estimate of $65.00. The average price target has increased by 11.88% over the past month. Analysts from Benchmark and Truist Securities have raised their price targets, while RBC Capital has both raised and maintained its targets. VSE's financials show strong revenue growth and net margin, but a lower than average Return on Equity (ROE).

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

REGN

Over the past 3 months, 14 Wall Street analysts have published their opinions on Regeneron Pharmaceuticals (NASDAQ:REGN), with an average 12-month price target of $920.0, a high of $1045.00, and a low of $800.00. The current average price target has increased by 4.74% from the previous average of $878.38. Analysts' ratings range from 'Buy' to 'Hold', with various actions taken including maintaining, raising, and lowering price targets. Regeneron is involved in developing treatments for various diseases and has several marketed products. Financially, the company shows strong performance with a high net margin and ROE, low debt-to-equity ratio, but a revenue growth rate lower than the Health Care sector average.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

ARMH

Arm Holdings' stock is trading lower following a downgrade from Buy to Hold by Deutsche Bank.

Portfolio Pulse from Bill Haddad

December 18, 2023 | 8:49 pm

CSIQ

ENPH

FSLR

NOVA

RUN

SEDG

SPWR

TAN

Goldman Sachs downgraded SunPower Corp (SPWR) to Sell with a price target of $4 due to doubts about its ability to continue operations, causing its shares to drop 35%. Despite this, Goldman Sachs remains positive on the solar sector, upgrading Sunnova Energy (NOVA) to Buy and Canadian Solar (CSIQ) to Neutral. Enphase Energy (ENPH) retains a Buy rating with a significant upside potential, while SolarEdge Technologies (SEDG) was downgraded to Sell. Sunrun (RUN) and First Solar (FSLR) maintained their Buy ratings, but their shares fell. The Invesco Solar ETF (TAN) is down around 35% this year.

Portfolio Pulse from Neil Dennis

December 18, 2023 | 8:33 pm

AMZN

FDX

UPS

FedEx Corp (NYSE:FDX) is expected to report Q2 revenue of $22.405 billion, a potential decline from the previous year's $22.814 billion. Analysts predict EPS of $4.20, up from $3.18 year-over-year. Despite six quarters of missing revenue estimates, FedEx has outperformed EPS estimates for five consecutive quarters. Morgan Stanley's analyst sees a potential miss across all segments, while a Citi analyst views FedEx as a top pick, citing cost initiatives and a potential Cyber Week boost. FedEx's performance will be compared to UPS's recent revenue decline and guidance cut. FedEx shares have risen 60% YTD, outperforming UPS's 7% decline. Amazon's emergence as the largest U.S. residential parcel delivery company is also noteworthy.

Portfolio Pulse from Chris Katje

December 18, 2023 | 8:09 pm

LUV

Southwest Airlines (NYSE:LUV) has received mixed analyst ratings in the last quarter, with 0 bullish, 3 somewhat bullish, 5 indifferent, 1 somewhat bearish, and 0 bearish. The average 12-month price target from 9 analysts is $29.33, down from the previous $32.11, indicating a negative sentiment shift. Analysts from firms like Citigroup, Raymond James, and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Despite the mixed ratings, Southwest Airlines has shown strong financial indicators such as a 4.9% revenue growth rate, a net margin of 2.96%, an ROE of 1.77%, an ROA of 0.53%, and a low debt-to-equity ratio of 0.84.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 8:00 pm

MIRM

HC Wainwright & Co. analyst Ed Arce has maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) but has reduced the price target from $60 to $58.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 7:34 pm

AYX

Needham analyst Mike Cikos has downgraded Alteryx (NYSE:AYX) from Buy to Hold, indicating a shift in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 7:29 pm